Meta Biomed Co. Ltd (059210) — Cash Flow-to-Debt Ratio
Meta Biomed Co. Ltd (059210) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of ₩1.05 Billion could theoretically repay 0% of its total liabilities (₩58.87 Billion) in one year. See Meta Biomed Co. Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Meta Biomed Co. Ltd Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Meta Biomed Co. Ltd across 14 annual periods. For the full cash flow conversion analysis, see Meta Biomed Co. Ltd cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Meta Biomed Co. Ltd (2011–2024)
Year-by-year debt coverage analysis for Meta Biomed Co. Ltd. Check 059210 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.27x | ₩22.63 Billion | ₩83.96 Billion | ▲ +51.6% |
| 2023 | 0.18x | ₩10.22 Billion | ₩57.46 Billion | ▲ +17.4% |
| 2022 | 0.15x | ₩9.16 Billion | ₩60.48 Billion | ▼ -39.1% |
| 2021 | 0.25x | ₩11.14 Billion | ₩44.80 Billion | ▲ +206.1% |
| 2020 | 0.08x | ₩4.86 Billion | ₩59.88 Billion | ▲ +41.8% |
| 2019 | 0.06x | ₩2.86 Billion | ₩50.02 Billion | ▲ +151.7% |
| 2018 | -0.11x | ₩-5.28 Billion | ₩47.72 Billion | ▼ -3180.8% |
| 2017 | 0.00x | ₩-248.51 Million | ₩73.65 Billion | ▼ -104.6% |
| 2016 | 0.07x | ₩5.03 Billion | ₩68.49 Billion | ▼ -6.3% |
| 2015 | 0.08x | ₩4.93 Billion | ₩62.91 Billion | ▲ +1975.5% |
| 2014 | 0.00x | ₩-296.24 Million | ₩70.85 Billion | ▼ -108.1% |
| 2013 | 0.05x | ₩3.71 Billion | ₩72.25 Billion | ▼ -16.1% |
| 2012 | 0.06x | ₩3.83 Billion | ₩62.54 Billion | ▼ -77.8% |
| 2011 | 0.28x | ₩4.10 Billion | ₩14.84 Billion | — |